Highest-materiality recent filing
60 Degrees files SAP for tafenoquine babesiosis trial; interim analysis criteria set
23 of 33 planned patients enrolled in randomized, placebo-controlled trial of tafenoquine for severe babesiosis (NCT0627370).
60 Degrees Pharmaceuticals Plans to Seek FDA Priority Review Voucher for Tafenoquine in Babesiosis
Company intends to apply for a Commissioner's National Priority Review Voucher if trial results support NDA submission by Q1 2028.
60 Degrees Pharmaceuticals appoints Eric Francois to Board of Directors
Eric Francois appointed to board effective May 13, 2026; compensation consistent with standard non-employee director arrangements.
60 Degrees Pharmaceuticals corrects beneficial ownership disclosure in March 13 prospectus
March 13 prospectus supplement incorrectly reported affiliate's beneficial ownership as 21,490 shares; correct is 23,367.
60 Degrees Pharmaceuticals files updated legal opinion for ATM program
Filed updated legal opinion of Sichenzia Ross Ference Carmel LLP regarding shares sold under ATM Program.
60 Degrees Pharmaceuticals files updated legal opinion for ATM program
Filed updated legal opinion from Sichenzia Ross Ference Carmel LLP regarding shares sold under ATM Program.
Received Nasdaq notice on Feb 11 confirming compliance with minimum bid price rule 5550(a)(2).
Nasdaq notifies 60 Degrees Pharmaceuticals of delisting for bid price rule violation
Nasdaq determined common stock failed $1.00 minimum bid price for 30 consecutive business days.
60 Degrees Pharmaceuticals to effect 1:4 reverse stock split effective Jan 20, 2026
Reverse split at 1:4 ratio effective Jan 20, 2026 at 12:01 AM ET before market open.
Company made investor presentation available on January 8, 2026, in connection with RedChip webinar.
60 Degrees Pharma shareholders approve reverse split, equity plan amendment at annual meeting
Five directors elected: Geoffrey Dow, Charles Allen, Cheryl Xu, Stephen Toovey, Paul Field.
60 Degrees Pharmaceuticals presents at H.C. Wainwright; no specific updates disclosed in filing
CEO Geoff Dow scheduled to present to investors starting September 9, 2025.
60 Degrees Pharmaceuticals enters $1.4M ATM offering with H.C. Wainwright, terminates prior ATM
Entered ATM Sales Agreement with H.C. Wainwright to sell up to $1,397,533 of common stock.
60 Deg Pharma closes $5M public offering, up to $10M with warrant exercise
Gross proceeds $5M from sale of 2,631,578 units (share/pre-funded warrant + warrants) at $1.90/unit.
60 Degrees Pharma enters 12-month option for castanospermine license with Florida State
Entered exclusive 12-month option to negotiate a royalty-bearing license for castanospermine purification technology.
60 Degrees Pharma raises $1.075M in registered direct offering plus warrants
Gross proceeds of $1.075 million from registered direct offering of 1,503,500 shares at $0.715 per share.
60 Degrees Pharmaceuticals closes $1.043M registered direct offering and warrant private placement
Issued 1,021,549 shares at $1.021/share; gross proceeds ~$1.043M.
60 Degrees Pharma announces IRB approval for Phase II study of tafenoquine in chronic babesiosis
IRB-approved open-label Phase II study (NCT06656351) evaluating tafenoquine for chronic babesiosis.
First patient enrolled in NCT06478641, an expanded access study of tafenoquine for persistent babesiosis after standard-of-care failure.
Proposal to approve exercise of warrants for up to 6,014,493 shares passed with 259,282 for, 14,312 against.
60 Degrees Pharmaceuticals launches 9-month promotional pilot for ARAKODA malaria drug
Nine-month pilot includes virtual sales reps and co-pay program to boost ARAKODA awareness and sales.
60 Degrees Pharmaceuticals raises ~$4M in private placement of common stock equivalents and warrants
Issued 2,898,551 pre-funded warrants and series A/B warrants at $1.38/share for gross proceeds of ~$4M.
60 Degrees Pharmaceuticals regains Nasdaq minimum bid price compliance
Received Nasdaq notice on Aug 26, 2024 confirming compliance with Listing Rule 5550(a)(2).
60 Degrees Pharma grants UK right of reference to ARAKODA NDA for SJ733 Phase IIb trial
Granted University of Kentucky right of reference to ARAKODA NDA for FDA review of data supporting SJ733 Phase IIb study.
60 Degrees Pharmaceuticals effects 1:12 reverse stock split to regain Nasdaq compliance
Reverse stock split at 1-for-12 ratio effective August 12, 2024; new CUSIP 83006G203.
60 Degrees Pharma awarded $311,862 U.S. Army contract for ARAKODA packaging validation
Awarded a fixed-price contract valued at $311,862 with U.S. Army Medical Materiel Development Activity for new bottle and replacement blister packaging of ARAKODA.
60 Degrees Pharma shareholders approve 1:5-1:12 reverse split and 5M share increase
All five director nominees elected; each received >3.6M votes for.
60 Degrees Pharma enrolls first patient in tafenoquine babesiosis study at Tufts Medical Center
IRB approval received for open-label expanded access study of tafenoquine in immunocompromised patients with persistent babesiosis.
60 Degrees Pharmaceuticals enrolls first patient in tafenoquine babesiosis trial
First patient enrolled in randomized, double-blind, placebo-controlled trial at Tufts Medical Center.
FDA granted orphan drug designation for tafenoquine for acute babesiosis; company qualifies for market exclusivity, tax credits, and exemption from certain FDA filing fees.
60 Degrees Pharma gets FDA comments on tafenoquine babesiosis trial; no material changes needed
FDA provided comments on the clinical trial protocol for tafenoquine in treating babesiosis on April 26, 2024.
FDA delays response to 60 Degrees Pharma's babesiosis trial protocol to April 2024
FDA communicated intention to respond to babesiosis trial protocol in April 2024, not March 2024 as anticipated.
60 Degrees Pharma receives Nasdaq bid price deficiency notice; 180-day cure period
Nasdaq notified SXTP that common stock failed to maintain $1.00 minimum bid price for 31 consecutive business days through Feb 27, 2024.
Animal studies will test tafenoquine efficacy against Candida spp, including drug-resistant Candida auris.
60 Degrees Pharmaceuticals closes $2.4M public offering of units and pre-funded units
Gross proceeds ~$2.4M; net proceeds ~$1.9M after underwriter discounts and expenses.
Following Jan 17 FDA meeting, 60 Degrees Pharma plans pivotal babesiosis study for tafenoquine
FDA Type C meeting on Jan 17, 2024 led to mutual alignment on design of pivotal study for tafenoquine in hospitalized babesiosis.
60 Degrees Pharmaceuticals regains Nasdaq minimum bid price compliance
Received Nasdaq letter on Jan 10, 2024 confirming compliance with Bid Price Rule 5550(a)(2).
60 Degrees Pharmaceuticals receives Nasdaq deficiency notice for bid price non-compliance
On Nov 2, 2023, Nasdaq notified SXTP that its common stock failed to maintain minimum $1.00 closing bid price for 30 consecutive business days through Nov 1, 2023.
60 Degrees suspends Phase IIB tafenoquine COVID-19 study; pivots to malaria and babesiosis
Company will not re-submit IND for Phase IIB study (ACLR8-LR) of tafenoquine in mild-to-moderate COVID-19 after FDA feedback made U.S. enrollment unfeasible.
Withdrew IND for ACLR8-LR Phase IIB study of tafenoquine for COVID-19 due to FDA comments on study design.
IPO of 1,415,095 units priced at $5.30/unit; each unit = 1 share + 1 tradeable warrant ($6.095 exercise) + 1 non-tradeable warrant ($6.36 exercise).
On May 13, 2026, the Board of Directors (the “Board”) of 60 Degrees Pharmaceuticals, Inc. (the “Company”) appointed Eric Francois to serve as a member of the Board, effective immediately.
Max materiality 0.90 · Median 0.55 · Most common event other_material